SEC Comment Letter 0000000000-23-003622 to TALPHERA, INC. (TLPH)

TALPHERA, INC.
Date: April 11, 2023 · CIK: 0001427925 · Accession: 0000000000-23-003622

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

April 11, 2023

Author

Not clearly detected

Form

UPLOAD

Company

TALPHERA, INC.

Letter

United States securities and exchange commission logo April 11, 2023 Raffi Asadorian Chief Financial Officer ACELRX PHARMACEUTICALS INC 25821 Industrial Boulevard Suite 400 Hayward, CA 94545 Re:ACELRX PHARMACEUTICALS INC Form 8-K filed March 30, 2023 Dear Raffi Asadorian: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
April 11, 2023
Raffi Asadorian
Chief Financial Officer
ACELRX PHARMACEUTICALS INC
25821 Industrial Boulevard
Suite 400
Hayward, CA 94545
Re:ACELRX PHARMACEUTICALS INC
Form 8-K filed March 30, 2023
Dear Raffi Asadorian:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io